Home › NCT07133893
Transcranial Photobiomodulation in Anxiety Disorders
Effects of Transcranial Photobiomodulation and Attention Bias Modification on Anxiety Symptoms and Brain Hemodynamics
Who can join
Ages 18 to 100 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * 18 years of age and older * State-Trait Anxiety Index (STAI) questionnaire score between 40-59 (indicates moderate sub-clinical anxiety) * Patient Health Questionnaire (PHQ-9) score between 1-9 (indicates minimal to mild sub-clinical depression) Exclusion Criteria: * STAI score less than 40 or greater than 59 * PHQ-9 score greater than 9 * Medication instability (i.e., medication change within 6 weeks) * Indicated suicidal ideation * Currently receiving tPBM treatment * Current pregnancy
About the study
The investigators have previously shown that safe, non-invasive methods of brain stimulation such as the administration of transcranial infrared light can result in improvements to cognition and emotion. The investigators hypothesize that transcranial photobiomodulation (tPBM) can be used in conjunction with attention bias assessment and modification to reduce anxiety symptoms in individuals with sub-clinical anxiety.
What is being tested
- Attention bias assessment and modification (behavioral)
- Transcranial photobiomodulation (device)
Sponsor: Francisco Gonzalez-Lima, PhD · Participants: 280 · Started: Sep 1, 2025
Contact the study team
- Francisco Gonzalez-Lima, Ph.D. · Phone: 512-537-5257
Official record on ClinicalTrials.gov — NCT07133893
Locations in the U.S.
| Texas | The University of Texas at Austin, Austin |
From ClinicalTrials.gov, data retrieved Oct 3, 2026. Each study sets its own eligibility; the study team decides who can join.